NSE · AAREYDRUGS · Healthcare
Aarey Drugs & Pharmaceuticals Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹484 Cr with net profit ₹4 Cr — a 0.83% net margin, versus 1.16% the period before.
Shareholding
As of 2026-06-30
- Promoter37.71%
- Public55.86%
- FII4.8%
- DII1.62%
13,478 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.99× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — ESM · ESM 2. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Drug Manufacturers - Specialty & Generic · ranked #1 of 15 by market cap · medians across 5 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Procter & Gamble Health Limited | ₹10,981 Cr | 116.08 | 20.94 | 62.32% | 23.22% |
| Medico Remedies Limited | ₹384 Cr | 65.15 | 5.06 | 17.38% | 6.36% |
| Par Drugs & Chemicals Ltd. | ₹118 Cr | 138.9 | 1.05 | 11.71% | 12.65% |
| Krebs Biochemicals & Industries Ltd. | ₹117 Cr | — | — | 10.4% | -71.34% |
| Ortin Global Limited | ₹12 Cr | — | 9.95 | -59.85% | -822.22% |
| Aarey Drugs & Pharmaceuticals Ltd.(this company) | — | 137.47 | 1.43 | — | — |
AI analysis
AI-generated · google/gemini-2.5-flashAarey Drugs & Pharmaceuticals Ltd. has a market capitalization of Rs 216 Cr. The company reported revenue of Rs 483.76 Cr and a profit margin of 95.7%. The promoter holding stands at 37.7101%, with public shareholders holding 56.493%. The stock is currently under ESM surveillance.
Positives
- +Revenue increased by 20.16% from Rs 402.5828 Cr in Mar 2024 to Rs 483.7557 Cr in Mar 2025.
- +The debt-to-equity ratio is low at 0.24.
- +The company's profit margin is 95.7% for the latest period.
- +Net profit increased by 16.53% from Rs 4.0239 Cr in Mar 2025 to Rs 4.6837 Cr in Mar 2024 (Note: This is based on chronological order of reporting in provided data).
Negatives
- −The P/E ratio of 138.2 is significantly high.
- −Return on capital employed (ROCE) is low at 5.198%.
- −Quarterly net profit for Dec 2025 decreased to Rs 0.57 Cr from Rs 1.02 Cr in Sept 2025, a decrease of 44.02%.
- −The promoter holding of 37.7101% is lower than the public holding of 56.493% as of March 31, 2026.
Financial Performance
Aarey Drugs & Pharmaceuticals Ltd. reported revenue of Rs 483.76 Cr. The company's net profit for the year ended Mar 2025 was Rs 4.0239 Cr, with an EPS of 10. The company's revenue declined to Rs 402.5828 Cr in Mar 2024 from Rs 421.6855 Cr in Mar 2023, representing a decrease of 4.53%. However, revenue increased to Rs 483.7557 Cr in Mar 2025. Net profit shows variability, with a figure of Rs 4.6837 Cr in Mar 2024 and Rs 4.0239 Cr in Mar 2025.
Profitability & Returns
The company has a P/E ratio of 138.2. Return on equity (ROE) is 263.8%, while return on capital employed (ROCE) is 5.198%. The profit margin for the latest period is 95.7%. Earnings per share (EPS) for the year ended Mar 2025 stood at 10, showing an increase from 1.49 in Mar 2023.
Balance Sheet
The book value per share is Rs 53.02. The debt-to-equity ratio is 0.24. This indicates a relatively low reliance on debt for financing. Further details on assets and liabilities are not provided in the available data.
Ownership & Pledges
As of March 31, 2026, promoter holding in Aarey Drugs & Pharmaceuticals Ltd. is 37.7101%. FII holding is 4.1757% and DII holding is 1.6212%, with total institutional holding at 5.7969%. There are no promoter pledges reported for the company.
Regulatory & Surveillance
The company is currently under ESM (Enhanced Surveillance Measure) surveillance, with the specific measure being ESM 2. This means the stock is subject to additional monitoring by regulatory authorities due to certain criteria being met.
Data as of — price: 2026-07-30 · financials: Mar 25 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Aarey Drugs & Pharmaceuticals Ltd.share price & fundamentals